Speech-Language Pathologists in Milford, ME Accepting Medicare
4 Speech-Language Pathologists found. Showing 1 - 4
 Mrs. Carolyn Sands Eaton, M.ED., M.A. CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 13 School St, Milford, ME 04461 Phone: 207-827-2252 |
 Therapeutic Learning Center, Inc. Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 78 Main Rd, Milford, ME 04461 Phone: 207-356-8211 |
Melissa Barthelemy, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 13 School St, Milford, ME 04461 Phone: 207-827-2252 |
Meagan J Grass, CF-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 78 Main Rd, Milford, ME 04461 Phone: 207-356-8211 |
News Archive
Political fight jeopardizes Mississippi's entire Medicaid program
The state's Democratic and Republican lawmakers are embroiled in a game of chicken that threatens to blow up the Medicaid program, which serves 700,000 poor Mississipians. Meanwhile, reports from Indiana, Montana and California detail other developments related to state officials' decisions about whether to expand the program under the health law.
Experts recommend removal of restrictions in accessing new hepatitis C therapies for drug users
Global health experts are today are calling for the removal of restrictions preventing people who use drugs from accessing new hepatitis C cures. So long as these restrictions exist, the goal of disease elimination will remain out of reach, they say.
Cyberonics, Imricor enter agreement to develop MRI compatible leads for VNS Therapy System
Cyberonics, Inc. today announced that it has entered into an exclusive technology license agreement with Imricor Medical Systems, Inc. to develop Magnetic Resonance Imaging ("MRI") compatible leads for use with the VNS Therapy System (Vagus Nerve Stimulation).
FDA approves new drug for treatment of lung disease caused by Mycobacterium avium complex
The U.S. Food and Drug Administration today approved a new drug, Arikayce, for the treatment of lung disease caused by a group of bacteria, Mycobacterium avium complex in a limited population of patients with the disease who do not respond to conventional treatment.
› Verified 1 days ago